The Latest SPAC News and Rumors: September 28, 2021


The Latest SPAC News and Rumors: September 28, 2021

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: SEC Gensler continues to express concern over SPACs; Revelation Biosciences receives approval to conduct Phase 2b viral challenge study

SEC’s Gensler Talks Up Crypto and SPAC Regulations

Securities and Exchange Commission Chairman Gary Gensler shed light on an array of hot-button topics during an interview on Monday, expressing his belief that “people will be hurt” if cryptocurrency markets are allowed operate beyond the remit of regulators, and voicing concerns that SPACs leave public market investors vulnerable.

Gensler expressed concern about the loose definitions around what SPACs can do with investors’ money. He noted how the structure incentivizes SPACs to find a merger deal “even if it’s not a particularly great merger”—potentially at the expense of the investors they are raising money from.

Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99

Revelation Biosciences Inc., a clinical-stage life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, announced today it has received approval from the Federal Agency for Medicines and Health Products and the local Committee of Medical Ethics in Belgium to conduct a Phase 2b influenza viral challenge study.

The Phase 2b, randomized, double-blind, influenza viral challenge study is planned in healthy volunteers. This viral challenge investigation will evaluate the potential efficacy of a single- and repeat-dose of REVTx-99 prophylaxis versus placebo on viral load and clinical illness influenza symptoms.

On August 30th, Revelation Biosciences entered into a definitive agreement to combine with Petra Acquisition, Inc. (NASDAQ:PAIC).